PhRMA Expresses IP Concerns For 40 Countries

The Pharmaceutical Research and Manufacturers of America (PhRMA)'s view on global intellectual property (IP) issues has remained largely unchanged over the past year, based on the association's latest Special 301 submission to the United States Trade Representative (USTR). The submission outlines the industry's concerns about countries' intellectual property regime deficiencies, including adherence to the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), measures in place to deal with counterfeit medicines, the speed at which IP disputes are resolved and general market access

To read the full article, please choose one of the following options: